Leah Croll, MD, Assistant Professor of Clinical Neurology at the Lewis Katz School of Medicine at Temple University, offered insight to ABC News on the U.S. Food and Drug Administration (FDA) granting accelerated approval to Leqembi, which showed in a large study that it could slow the rate of cognitive decline in people with the early stages of Alzheimer’s disease.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH